Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Governance Other
confidence 72%
filed 2026-09-23
Item 3.03
Ready Capital entered into a First Supplement to its Eighth Supplemental Indenture on September 18, 2026, with consent of majority holders of $100 million in 7.375% Senior Notes due 2027. The amendment modifies two key financial covenants: (i) permits a Recourse Debt to Equity Ratio up to 2.0x (relaxing prior constraints), and (ii) resets the minimum Consolidated Net Asset Value floor to $1.2 billion plus 75% of Net Equity Capital Activity. This is a material modification to the rights and obligations of security holders under the indenture, affecting covenant compliance thresholds that could influence the Company's financial flexibility and the noteholders' protective provisions. While the amendment was consensual (majority-approved), it materially alters the contractual terms governing the debt securities.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 98%
filed 2026-09-23
EX-99.1
FEMSA announced the successful issuance of CHF 300 million in 5-year senior unsecured bonds in the Swiss bond market, bearing interest at 107 basis points over benchmark for a yield of 1.73%. This is a material creation of a direct financial obligation and represents a significant debt capital-raising event that would affect a reasonable investor's assessment of the company's capital structure and financial flexibility.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 85%
filed 2026-09-23
Item 1.01
Crestline Lending Solutions entered into Amendment No. 2 to its Loan Financing and Servicing Agreement on September 18, 2026, increasing the Committed Facility Amount from $350 million to $550 million and the Maximum Facility Amount from $400 million to $600 million, while adding three new lenders (Western Alliance Bank, East West Bank, and Apple Bank). This material amendment expands the company's borrowing capacity and direct financial obligations.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-23
Item 5.02
The Company's Board approved the appointment of Howard Sudnow as an independent director effective at the Merger Effective Time (expected Q4 2026), with detailed qualifications and compensation terms disclosed. While the filing occurs in the context of a pending merger, the principal disclosed action is the appointment of a new director to the Board, making this an executive appointment event.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-23
Item 5.02
Enhanced Group Inc. announced multiple board-level appointments: Michael Sepso as a new director and Audit Committee member (with a $370,000 initial RSU grant), James Simpson as new Chairman of the Board, and Anthony D. Eisenberg as Chair of the Audit Committee. The appointments also coincided with the resignations of two directors, James J. Murren and Christian Angermayer (the former Chairman).
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-23
Item 5.02
Amy Miller was elected as a director representing Wheatland Rural Electric Association on Tri-State's Board of Directors, effective September 22, 2026. This is a director appointment disclosed under Item 5.02, and board composition changes are material to investors assessing governance and oversight.
View raw filing on EDGAR →
6-K
Earnings release
confidence 75%
filed 2026-09-23
EX-99.1
This is a press release announcing positive clinical trial results for ACI-7104 in the VacSYn Phase 2 trial. While not a financial earnings release, it discloses material clinical trial outcomes (all primary endpoints met, 100% immunogenicity response rate, CSF antibody penetration, target engagement signals) that would significantly affect investor assessment of the company's lead program and development trajectory. The disclosure of clinical milestones and regulatory pathway discussions is material to a biopharmaceutical company's valuation and prospects.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-23
AstraZeneca announces European Commission approval of Trixeo (budesonide/glycopyrronium/formoterol) for asthma maintenance treatment in patients 12 years and older. This is a significant regulatory milestone and product approval that expands the company's respiratory portfolio and addresses a large unmet medical need (43 million asthma patients in Europe). While not fitting a discrete event category like M&A or earnings, this material regulatory approval of a new indication for an established product is a key operational and commercial milestone that would affect investor assessment of the company's growth prospects and pipeline execution.
View raw filing on EDGAR →
6-K
Exec departure
confidence 95%
filed 2026-09-23
The filing announces that Joanne Wilson is stepping down from her role as Chief Financial Officer and Executive Director of WPP to take up the CFO position at Diageo plc. While the announcement also notes that a search for her successor has commenced, the principal disclosed action is the departure of a named executive officer from a material C-suite position. The 12-month notice period and orderly transition do not change the fundamental nature of the event as an executive departure.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-09-23
Diageo announces the appointment of Joanne Wilson as Chief Financial Officer, joining the Board and Executive Committee in 2027, replacing Nik Jhangiani. The announcement includes detailed compensation terms (£900,000 salary, pension, incentive plans, and replacement awards), confirming this is a material executive appointment. The CFO role is a named executive officer position critical to investor assessment of management continuity and financial leadership.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-09-23
Pearson announces the appointment of three new Non-Executive Directors (Michael Barkin, Vivek Sharma, and Alex Svensson) effective 1 October 2026. This is a governance event involving the appointment of directors to the Board, which is material to investors as it affects board composition and strategic direction. The announcement explicitly identifies these as new Board members joining the Pearson Board of Directors.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-09-23
EX-99.1
This is a notification of a relevant change to a significant shareholder under AIM Rules. BlackRock, Inc. crossed a notification threshold on September 21, 2026, increasing its total voting rights from 6.98% to 7.01% (combining direct shares at 4.94%, securities lending at 0.94%, and CFDs at 1.12%). While this is a governance disclosure concerning shareholder composition, it does not fit the specific categories of exec_appointment, exec_departure, exec_compensation, or shareholder_vote_results. The crossing of a 7% threshold by a major institutional investor is material to shareholders' understanding of the company's ownership structure and potential influence.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-09-23
Item 5.02
Dean Zikria, a current board member, was appointed as Interim Chief Executive Officer of Valion Bio effective September 22, 2026. The appointment also includes compensatory arrangements (monthly fee of $23,333, 50,000 RSUs, and potential bonus) and is accompanied by related board leadership transitions including Thomas Jensen's appointment as Board Chair and Sheryle Bolton's resignation.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-23
Item 5.02
The filing discloses the appointment of Vidhyadhar Mitta to the Board of Directors effective September 21, 2026. Although Mr. Mitta previously served as a director, the principal disclosed action is his appointment/re-appointment to the Board. The filing also references a prior Debt Exchange Agreement from October 2025 in which Mr. Mitta converted debt to preferred stock, but the core event triggering this 8-K Item 5.02 disclosure is the director appointment itself.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-23
Item 1.01
Nocera entered into a Strategic Partnership and Joint Distribution Agreement with Taiwan-based E-PRO Display on September 17, 2026, appointing Nocera as a non-exclusive worldwide distributor of pre-owned iPhone 17 Pro handsets valued at approximately $520.5 million. This material distribution partnership establishes a new business channel and represents a foundational step in the company's strategic positioning for AI distribution.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-09-23
Item 2.02
NeoVolta issued a press release on September 23, 2026, announcing financial results for the fourth quarter and fiscal year ended June 30, 2026. The disclosure includes detailed financial highlights (58% year-over-year revenue growth to $13.3 million, GAAP net loss of $21.5 million, and Adjusted EBITDA of $(12.8) million), consolidated balance sheets, statements of operations, and cash flow statements. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial performance and operational trajectory.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-09-23
Item 7.01
The filing discloses a pending share exchange transaction between Xenetic Biosciences and Santersus AG, with a definitive Share Exchange Agreement dated September 14, 2026. The transaction involves Santersus becoming a wholly owned subsidiary of Xenetic, with pre-transaction Santersus shareholders expected to own approximately 85% of the combined company. The transaction is valued at $141 million and is expected to close in Q4 2026, constituting a material acquisition/change of control event.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-09-23
Item 8.01
Gossamer Bio announced submission of its first New Drug Application (NDA) to the FDA for seralutinib in PAH treatment in September 2026, supported by Phase 3 PROSERA and Phase 2 TORREY studies. This is a material regulatory and operational milestone for a clinical-stage biopharmaceutical company whose future depends entirely on seralutinib's success, as disclosed in the forward-looking statements. While not a specific named event type, this represents a significant operational/regulatory development that would affect a reasonable investor's assessment of the company's progress toward commercialization.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-09-23
Item 1.01
KLX Energy Services adopted a limited-duration stockholder rights plan (poison pill) effective immediately with a 10% beneficial ownership trigger in response to rapid stock accumulation by a new investor following expiration of a $125 million backstopped rights offering. The Board implemented this defensive governance measure to protect against potential hostile acquisition tactics and preserve board discretion during the post-deleveraging period.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-23
Item 3.02
Blue Owl Credit Income Corp. completed an unregistered private placement of 191,466 shares of Class I common stock for $1.75 million, exempt under Section 4(a)(2) and Regulation S. This equity issuance dilutes existing shareholders and represents a material capital raise affecting the registrant's capitalization structure.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 92%
filed 2026-09-23
Item 8.01
The board declared monthly distributions payable in October and November 2026 to shareholders across Class S, D, and I share classes at $0.070100 per share gross. This routine but material dividend declaration is consistent with the registrant's distribution policy as a closed-end credit fund.
View raw filing on EDGAR →
8-K
Financial Other
confidence 72%
filed 2026-09-23
Item 8.01
Holley disclosed a voluntary prepayment of $10 million on its first lien term loan facility on September 22, 2026, as part of a broader deleveraging program ($125 million repaid since 2023). While this is a financial event involving debt reduction, it does not fit the specific `debt_issuance` category (which covers creation of new obligations) or `covenant_breach` (which covers defaults). The prepayment is a positive capital allocation decision reducing existing debt, generating approximately $5 million in annualized interest savings and advancing the company's leverage targets. This is material to investors assessing the registrant's financial health and capital strategy, but lacks the specificity of a named financial event type, making `financial_other` the most appropriate classification.
View raw filing on EDGAR →
8-K
Material Impairment
confidence 98%
filed 2026-09-23
Item 2.06
The filing explicitly discloses a material impairment charge of $3.0–$3.5 million related to the cessation of The Win Zone sweepstakes product. The Company determined that the carrying value of internal-use software assets was not recoverable and reduced their useful life, triggering a pre-tax impairment charge under GAAP. This is a classic material_impairment event under Item 2.06.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-23
Item 7.01
Aurora disclosed an Analyst and Investor Day event in Dallas featuring demonstrations of its driverless trucking operations, customer panels, and a 2030 vision targeting 30,000 driverless trucks with multi-billion dollar revenue. While the disclosure itself is a routine investor relations event (Item 7.01, Regulation FD), the substantive content—including commercial milestones (200 trucks by end of 2026, 500-truck DaaS agreement with Hirschbach), hardware scaling achievements, and strategic partnerships with PACCAR and Volvo—represents material operational and strategic developments that would affect a reasonable investor's assessment of Aurora's commercial progress and market position.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-09-23
Item 3.03
Nauticus Robotics approved and implemented a 1-for-6 reverse stock split effective September 24, 2026, following shareholder approval at the May 27, 2026 annual meeting. The primary objective is to increase the share price to comply with Nasdaq Capital Market's minimum bid price requirement and mitigate delisting risk.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-23
Item 5.02
The filing discloses the appointment of Dritan Muneka as the Company's Principal Accounting Officer (PAO) and Corporate Controller, effective September 30, 2026, following Robert Rico's resignation. While both a departure and appointment occur, the principal disclosed action centers on the appointment of a new PAO—a key accounting leadership role—with detailed background information on the appointee's qualifications and experience at KPMG. The appointment of a PAO is material to investors' assessment of the registrant's financial reporting controls and governance.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-09-23
Item 3.02
Blue Owl Technology Income Corp. completed an unregistered sale of 89,128 shares of Class I common stock to feeder vehicles as of September 1, 2026, exempt under Section 4(a)(2) and Regulation S.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 92%
filed 2026-09-23
Item 8.01
The board declared monthly distributions payable in October and November 2026 to shareholders across three share classes (Class S, D, and I), with per-share amounts ranging from $0.067963 to $0.074775.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-09-23
Item 1.01
QuidelOrtho entered into Amendment No. 1 to its existing credit agreement on September 23, 2026, which materially modifies the terms of its $3.3 billion financing package (Term Loan A Facilities, Term Loan B, and Revolving Credit Facility). While technically an amendment rather than a new issuance, the amendment resets financial covenant levels through September 2029, adjusts interest rates and commitment fees, and adds additional restrictions to financial covenants—all material modifications to the company's direct financial obligations. This is disclosed under Item 1.01 (Entry into a Material Definitive Agreement) and would materially affect a reasonable investor's assessment of the company's debt structure and financial flexibility.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 85%
filed 2026-09-23
Item 3.01
The filing discloses a transfer of listing from Nasdaq Global Market to Nasdaq Capital Market, which is a downgrade in listing tier. While framed as an "approval" and "transfer," this represents a failure to maintain continued listing standards on the higher-tier market and constitutes a material change in the company's exchange listing status. The transfer to the Capital Market tier signals the company no longer meets the financial or governance requirements of the Global Market.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-23
Item 3.02
The filing discloses an unregistered sale of equity securities totaling approximately $205.3 million across three share classes (Class I-Series 1, Class S, and Class D) to investors for cash on September 1, 2026. The sale was exempt under Section 4(a)(2) and Regulations D and S, which are hallmarks of private placements. The company notes it has raised approximately $7.979 billion since inception through such continuous private offerings, indicating material capital-raising activity that dilutes existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-23
Item 3.02
The filing discloses an unregistered sale of equity securities totaling approximately $268.2 million across multiple share classes (Class I-Series 1, Class U, Class D, and Class S Shares) to investors on September 1, 2026, exempt under Section 4(a)(2) and Regulations D and S. This is a classic dilutive private placement by a private equity fund vehicle, and the magnitude ($268M in a single transaction, $10.9B cumulatively since inception) is material to investors assessing the registrant's capital structure and ownership dilution.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-09-23
Item 8.01
The filing announces the expiration of the 40-day "go-shop" period under a definitive merger agreement dated August 13, 2026, pursuant to which affiliates of Thoma Bravo will acquire Accelerant in an all-cash transaction valued at more than $4 billion. This is a material acquisition event that will result in Accelerant becoming a private company and delisting from the NYSE. The disclosure confirms the merger remains on track to close in the first half of 2027, subject to customary closing conditions and shareholder approval.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 88%
filed 2026-09-23
Item 1.01
Teamshares issued $225 million in Series A Preferred Stock on September 23, 2026, structured as perpetual, non-voting, non-convertible preferred equity with a 16.0%-18.0% annual dividend rate and specified redemption terms. Although technically preferred equity, the instrument functions as a fixed-obligation financing vehicle with mandatory dividend payments and debt-like characteristics, subordinated to senior debt and characterized by the company as 'non-dilutive capital' for funding acquisitions.
View raw filing on EDGAR →
8-K
Governance Other
confidence 80%
filed 2026-09-22
Item 5.02
Wesley Bush was appointed as independent Lead Director of the GE Aerospace Board effective September 21, 2026, with Tom Horton remaining on the Board. Judson Althoff was appointed to the Audit Committee on the same date. These board-level governance changes affect the company's leadership structure and board composition.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-09-22
Item 5.02
The filing discloses Board ratification of compensation increases for two named executives: Raymond John "Trey" Adams III (President and CEO) and Todd Scruggs (Senior Vice President and CFO). The increases include base salary adjustments, enhanced target bonuses, and increased long-term equity incentive awards, all effective October 1, 2026. This is a direct disclosure of compensatory arrangements for officers under Item 5.02(e), making it an exec_compensation event.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-09-22
Item 2.02
MillerKnoll issued a press release on September 22, 2026, announcing financial results for the first quarter of fiscal 2027 ended August 29, 2026. The disclosure includes detailed quarterly financial statements (condensed consolidated statements of operations, cash flows, and balance sheets), segment results, guidance for Q2 and full year FY2027, and management commentary from the Interim CEO. This is a standard quarterly earnings release attached as Exhibit 99.1 to Item 2.02, which is material to investors assessing the company's financial performance and outlook.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-22
Item 5.02
The disclosure centers on the appointment of Robert W. Hau as Executive Vice President and Chief Financial Officer effective November 1, 2026, following his recent promotion to Senior Vice President, Finance. While the section also mentions Robert P. Fishman's concurrent resignation from the Interim CFO role, the principal action disclosed is Hau's appointment to a material C-suite position. The detailed compensation package (base salary $775,000, $2.5M equity award, $200K new hire bonus) and executive background underscore the materiality of this appointment to investors.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-09-22
Item 2.02
THOR Industries issued a press release on September 22, 2026 announcing financial results for the fourth quarter and full year ended July 31, 2026, reporting consolidated net sales of $9.61 billion, net income of $177.5 million, and diluted EPS of $3.38, along with detailed segment results and management commentary.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-09-22
Item 2.02
KB Home issued a press release on September 22, 2026, announcing third quarter and nine-month financial results for the period ended August 31, 2026, including revenues of $1.30 billion, diluted EPS of $1.05, and detailed operating metrics. The disclosure is a standard quarterly earnings announcement with consolidated financial statements, balance sheet data, and forward guidance, filed under Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-09-22
Item 8.01
Cognex announced entry into a definitive agreement to acquire RealSense, Inc. for approximately $500 million in an all-cash transaction, financed from existing cash and expected to close in Q4 2026. The strategic acquisition expands Cognex into the high-growth robotic perception market, with RealSense expected to generate $80–90 million in 2026 revenue.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-22
Item 5.02
The filing discloses the election of Worthing F. Jackman to the Board of Directors effective immediately on September 22, 2026, along with his appointment to two Board committees. While the section also mentions Dr. Kasarda's retirement, the substantive focus and primary action is Jackman's appointment as a director with significant prior executive experience (former CEO of Waste Connections, current board member of Quanta Services and Executive Chair of WillScot Holdings). This is a material governance event affecting board composition.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-09-22
Item 7.01
Ligand acquired royalty and milestone payment rights relating to Santen's Ryjunea® from Sydnexis for $23 million upfront. This is a material acquisition of intellectual property and economic rights—a transaction that expands Ligand's royalty portfolio and creates a new revenue stream. The press release emphasizes this as a strategic acquisition of "the type of differentiated asset" for Ligand's royalty aggregation business, making it a material M&A activity despite being structured as a royalty rights acquisition rather than a traditional company acquisition.
View raw filing on EDGAR →
8-K
Earnings release
confidence 92%
filed 2026-09-22
Item 7.01
NN, Inc. issued a press release on September 22, 2026 announcing raised full-year 2026 guidance for Net Sales ($470–$490M, up from $460–$480M) and Adjusted EBITDA ($58–$68M, up from $55–$65M), accompanied by an investor presentation for the D.A. Davidson conference. While technically a guidance update rather than reported results, the press release and presentation constitute a material earnings-related disclosure that would affect investor assessment of the company's financial performance and outlook. The disclosure includes detailed financial metrics, segment performance, and forward-looking guidance comparable to an earnings announcement.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-22
EX-99.1
Diana Shipping announces a time charter contract for the m/v DSI Polaris with Dai An Ocean Shipping at US$18,000 per day (gross) for a period until May 1, 2028 to June 30, 2028, expected to generate approximately US$10.37 million in gross revenue. This is a material operational/commercial contract that affects the Company's vessel employment and revenue generation, but does not constitute a discrete event type such as M&A, debt issuance, or earnings release—it is a routine vessel charter arrangement typical of the Company's shipping business operations.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-22
Item 7.01
LabCorp discloses CMS's release of preliminary Clinical Laboratory Fee Schedule payment rates for 2027–2029 under PAMA, which the Company characterizes as imposing "steep annual payment cuts that threaten patient access to laboratory services." The Company reaffirms its long-term financial outlook (5–8% revenue growth, 75–150 bps margin expansion, 8.5–11.5% EPS growth through 2029), indicating it has already factored this regulatory pressure into guidance. This is a material regulatory/operational event affecting the Company's business environment and reimbursement landscape, but it does not fit the specific categories of debt covenant breach, going concern, material impairment, or other defined event types. The disclosure is primarily forward-looking guidance and regulatory commentary rather than a discrete operational action or restructuring.
View raw filing on EDGAR →
8-K
Financial Other
confidence 72%
filed 2026-09-22
Item 1.01
The disclosure describes entry into a Capital Contribution Agreement among Exeter Finance LLC, EFCAR LLC, and four Exeter Automobile Receivables Trusts, permitting EFCAR to make capital contributions to the trusts as an equity holder. This is a material financial arrangement affecting the registrant's capital structure and obligations to the securitization trusts, but does not fit the specific categories of debt issuance, M&A activity, or other named financial events. It is clearly financial in nature and material to investors assessing the registrant's financial commitments.
View raw filing on EDGAR →
8-K
Financial Other
confidence 72%
filed 2026-09-22
Item 1.01
The disclosure describes entry into a Capital Contribution Agreement among Exeter Finance LLC, EFCAR LLC, and four Exeter Automobile Receivables Trusts, permitting EFCAR to make capital contributions to the trusts as an equity holder. This is a material financial arrangement affecting the registrant's capital structure and obligations to the securitization trusts, but does not fit the specific categories of debt issuance, M&A activity, or other named financial events. It is clearly financial in nature rather than operational, legal, or governance.
View raw filing on EDGAR →
8-K
Financial Other
confidence 72%
filed 2026-09-22
Item 1.01
The disclosure describes entry into a Capital Contribution Agreement among Exeter Finance LLC, EFCAR, LLC, and four Exeter Automobile Receivables Trusts, permitting EFCAR to make capital contributions to the trusts as an equity holder. This is a material financial arrangement affecting the registrant's capital structure and obligations to securitization vehicles, but does not fit the specific categories of debt issuance, M&A activity, or other named financial events—making it a financial_other event.
View raw filing on EDGAR →
8-K
Financial Other
confidence 72%
filed 2026-09-22
Item 1.01
The disclosure describes entry into a Capital Contribution Agreement among Exeter Finance LLC, EFCAR LLC, and four Exeter Automobile Receivables Trusts, permitting EFCAR to make capital contributions to the trusts as an equity holder. This is a material financial arrangement affecting the registrant's capital structure and obligations, but does not fit the specific categories of debt issuance, M&A activity, or other named financial events—it is a capital contribution arrangement within a securitization structure.
View raw filing on EDGAR →